Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals (Nasdaq: TARS) is a commercial-stage biopharmaceutical company that develops and commercializes therapeutics, beginning in eye care. Its marketed product, XDEMVY (lotilaner ophthalmic solution), is an eye drop approved in the United States to treat Demodex blepharitis and is sold to patients… From the company’s description.
Over the twelve months to Sep 30, 2026, Tarsus Pharmaceuticals, Inc. reported revenue of $682.20M, up 86.3% from a year earlier, and a net loss of $702.23M. Its operating margin was −102.0%, and operations generated $49.90M in cash. In fiscal 2025, it reported revenue of $451.36M, up 146.7% from fiscal 2024, and a net loss of $66.42M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Tarsus Pharmaceuticals, Inc. does
In the company’s own words
Tarsus Pharmaceuticals (Nasdaq: TARS) is a commercial-stage biopharmaceutical company that develops and commercializes therapeutics, beginning in eye care. Its marketed product, XDEMVY (lotilaner ophthalmic solution), is an eye drop approved in the United States to treat Demodex blepharitis and is sold to patients through eye care professionals. The company’s pipeline includes TP-04, an investigational lotilaner ophthalmic gel in Phase 2 development for ocular rosacea, and TP-05, an investigational oral lotilaner tablet being developed for Lyme disease prevention and community malaria reduction. Tarsus also evaluates XDEMVY for Demodex blepharitis in patients with meibomian gland disease and has licensed TP-03 rights for potential treatment of Demodex blepharitis and meibomian gland disease in China to GrandPharma. The company operates as a single business focused on therapeutic development and commercialization. In fiscal 2025, XDEMVY generated more than $646 million in net product sales since its August 2023 launch. Its website is https://tarsusrx.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- IRVINE, CA
- Fiscal year end
- December
- CIK
- 1819790
- SIC
- 2836
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Tarsus Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Tarsus Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Tarsus Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Tarsus Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Tarsus Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”